Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Urologic ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Cancer statistics, 2022.CA Cancer J Clin. 2022; 72: 7-33
- Evaluation of the New American Urological Association Guidelines Risk Classification for Hematuria | J Urol.(Available at:) (Accessed April 25, 2022)
- Microhematuria: AUA/SUFU Guideline.J Urol. 2020; 204: 778-786
- Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline.J Urol. 2016; 196: 1021-1029
- Optimal Trial Design for Studying Urinary Markers ...: Find It! Options.(Available at:) (Accessed April 25, 2022)
- Urinary-based tumor markers enhance microhematuria risk stratification according to baseline bladder cancer prevalence.Urol Oncol Semin Orig Investig. 2021; 39: 787.e1-787.e7
- Urinary nuclear matrix protein 22 as a new marker for the screening of urothelial cancer in patients with microscopic hematuria.Int J Urol. 1999; 6: 173-177
- Evaluation of the NMP22 BladderChek test for detecting bladder cancer: a systematic review and meta-analysis.Oncotarget. 2017; 8: 100648-100656
- Detection of Bladder Cancer Using a Point-of-Care Proteomic Assay.JAMA. 2005; 293: 810-816
- Urinary Biomarkers for Diagnosis of Bladder Cancer: A Systematic Review and Meta-analysis.Ann Intern Med. 2015; 163: 922-931
- Bladder cancer screening in a high risk asymptomatic population using a point of care urine based protein tumor marker.J Urol. 2009; 182 ([discussion: 58]): 52-57
- Diagnostic accuracy of cytokeratin-19 fragment (CYFRA 21-1) for bladder cancer: a systematic review and meta-analysis.Tumour Biol J Int Soc Oncodevelopmental Biol Med. 2015; 36: 3137-3145
- Molecular markers for bladder cancer screening, early diagnosis, and surveillance: the WHO/ICUD consensus.Urol Int. 2015; 94: 1-24
- UroVysion FISH test for detecting urothelial cancers: Meta-analysis of diagnostic accuracy and comparison with urinary cytology testing.Urol Oncol Semin Orig Investig. 2008; 26: 646-651
- Can urinary biomarkers replace cystoscopy?.World J Urol. 2019; 37: 1741-1749
- A multigene urine test for the detection and stratification of bladder cancer in patients presenting with hematuria.J Urol. 2012; 188: 741-747
- The Diagnostic Performance of Cxbladder Resolve, Alone and in Combination with Other Cxbladder Tests, in the Identification and Priority Evaluation of Patients at Risk for Urothelial Carcinoma.J Urol. 2021; 206: 1380-1389
- Validation of an mRNA-based Urine Test for the Detection of Bladder Cancer in Patients with Haematuria.Eur Urol Oncol. 2021; 4: 93-101
- Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer.Cell. 2017; 171 (e25): 540-556
- Urine cell-free DNA integrity as a marker for early bladder cancer diagnosis: preliminary data.Urol Oncol. 2013; 31: 1744-1750
- FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer.J Pathol. 2007; 213: 91-98
- Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome.Eur Urol. 2014; 65: 360-366
- Clinical evaluation of Bladder CARE, a new epigenetic test for bladder cancer detection in urine samples.Clin Epigenetics. 2021; 13: 84
- Bladder cancer detection in urine using DNA methylation markers: a technical and prospective preclinical validation.Clin Epigenetics. 2022; 14: 19
- Gene expression signature in urine for diagnosing and assessing aggressiveness of bladder urothelial carcinoma - PubMed.(Available at:) (Accessed May 7, 2022)
- Carbonic anhydrase IX in bladder cancer: a diagnostic, prognostic, and therapeutic molecular marker - PubMed.(Available at:) (Accessed May 7, 2022)
- Urinary carbonic anhydrase IX splicing messenger RNA variants in urogenital cancers - PubMed.(Available at:) (Accessed May 7, 2022)
- Carbonic anhydrase IX as a diagnostic urinary marker for urothelial bladder cancer - PubMed.(Available at:) (Accessed May 7, 2022)
- Urine survivin as a diagnostic biomarker for bladder cancer: a systematic review.BJU Int. 2012; 110: 630-636
- Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer.J Urol. 2004; 171: 626-630
- Clinical experience with survivin as a biomarker for urothelial bladder cancer.World J Urol. 2010; 28: 399-404
- A urinary microRNA signature can predict the presence of bladder urothelial carcinoma in patients undergoing surveillance | British Journal of Cancer.(Available at:) (Accessed May 7, 2022)
- Urine miRNA as a potential biomarker for bladder cancer detection – a meta-analysis.Cent Eur J Urol. 2018; 71: 177-185
- Promoter hypermethylation of HS3ST2, SEPTIN9 and SLIT2 combined with FGFR3 mutations as a sensitive/specific urinary assay for diagnosis and surveillance in patients with low or high-risk non-muscle-invasive bladder cancer.BMC Cancer. 2016; 16: 704
- A Prospective Blinded Evaluation of Urine-DNA Testing for Detection of Urothelial Bladder Carcinoma in Patients with Gross Hematuria.Eur Urol. 2016; 70: 916-919
- Evaluation of an Epigenetic Profile for the Detection of Bladder Cancer in Patients with Hematuria | J Urol.(Available at:) (Accessed May 7, 2022)
- Surveillance for Recurrent Bladder Cancer Using a Point-of-Care Proteomic Assay.JAMA. 2006; 295: 299-305
- Clinical comparison of noninvasive urine tests for ruling out recurrent urothelial carcinoma.Urol Oncol Semin Orig Investig. 2017; 35: 531.e15-531.e22
- The role of BTA stat Test in follow-up of patients with bladder cancer: results from FinnBladder studies.World J Urol. 2008; 26: 45-50
- Bladder tumour antigen (BTA stat) test compared to the urine cytology in the diagnosis of bladder cancer: A meta-analysis.Can Urol Assoc J. 2014; 8: E347-E352
- Urine Sediment Smears as a Diagnostic Procedure in Cancers of the Urinary Tract.(Available at:) (Accessed May 8, 2022)
- Is the performance of urinary cytology as high as reported historically? A contemporary analysis in the detection and surveillance of bladder cancer.Urol Oncol Semin Orig Investig. 2014; 32: 27.e1-27.e6
- The Value of the UroVysion® Assay for Surveillance of Non–Muscle-Invasive Bladder Cancer.Eur Urol. 2008; 54: 402-408
- A Novel Urine-Based Assay for Bladder Cancer Diagnosis: Multi-Institutional Validation Study.Eur Urol Focus. 2018; 4: 388-394
- Performance Characteristics of a Multigene Urine Biomarker Test for Monitoring for Recurrent Urothelial Carcinoma in a Multicenter Study | J Urol.(Available at:) (Accessed May 7, 2022)
- Cell-free microRNAs in urine as diagnostic and prognostic biomarkers of bladder cancer.Int J Oncol. 2012; 41: 1871-1878
- Detection of multiple mutations in urinary exfoliated cells from male bladder cancer patients at diagnosis and during follow-up.Oncotarget. 2016; 7: 67435-67448
- Mp13-15 molecular urine cytology – bladder epicheck is a novel molecular diagnostic tool for monitoring of bladder cancer patients.J Urol. 2016; 195: e140
- A Panel of Three Markers Hyper- and Hypomethylated in Urine Sediments Accurately Predicts Bladder Cancer Recurrence.Clin Cancer Res. 2014; 20: 1978-1989
- FGFR3, TERT and OTX1 as a Urinary Biomarker Combination for Surveillance of Patients with Bladder Cancer in a Large Prospective Multicenter Study.J Urol. 2017; 197: 1410-1418
- Clinical Utility of Fluorescent in situ Hybridization for the Surveillance of Bladder Cancer Patients Treated with Bacillus Calmette-Guérin Therapy.Eur Urol. 2007; 52: 752-759
- Monitoring intravesical therapy for superficial bladder cancer using fluorescence in situ hybridization.J Urol. 2005; 173: 401-404
- Use of Fluorescence In Situ Hybridization to Predict Response to Bacillus Calmette-Guérin Therapy for Bladder Cancer: Results of a Prospective Trial.J Urol. 2012; 187: 862-867
- Evaluation of the Fluorescence In Situ Hybridization Test to Predict Recurrence and/or Progression of Disease after bacillus Calmette-Guérin for Primary High Grade Nonmuscle Invasive Bladder Cancer: Results from a Prospective Multicenter Trial.J Urol. 2019; 202: 920-926
- Reflex ImmunoCyt Testing for the Diagnosis of Bladder Cancer in Patients with Atypical Urine Cytology.Eur Urol. 2013; 63: 936-940
- Prospective Evaluation of the Clinical Usefulness of Reflex Fluorescence In Situ Hybridization Assay in Patients With Atypical Cytology for the Detection of Urothelial Carcinoma of the Bladder | J Urol.(Available at:) (Accessed May 25, 2022)
- Prospective Validation of the Clinical Usefulness of Reflex Fluorescence In Situ Hybridization Assay in Patients With Atypical Cytology for the Detection of Urothelial Carcinoma of the Bladder.J Urol. 2010; 183: 62-67
- Yair Lotan. Evaluation of Cxbladder and Adjudication of Atypical Cytology and Equivocal Cystoscopy.Eur Urol. 2019; 76: 238-243
- Optimization of Nonmuscle Invasive Bladder Cancer Recurrence Detection Using a Urine Based FGFR3 Mutation Assay.J Urol. 2011; 186: 707-712
- Liquid Biopsy Analysis of FGFR3 and PIK3CA Hotspot Mutations for Disease Surveillance in Bladder Cancer.Eur Urol. 2017; 71: 961-969
- Cytokine Panel for Response to Intravesical Therapy (CyPRIT): Nomogram of Changes in Urinary Cytokine Levels Predicts Patient Response to Bacillus Calmette-Guérin.Eur Urol. 2016; 69: 197-200
- Urinary Protein Biomarker Panel for the Detection of Recurrent Bladder Cancer.Cancer Epidemiol Biomarkers Prev. 2014; 23: 1340-1345
- Use of a Multiplexed Molecular Biomarker Test Cxbladder.in: Real World Decision making to provide clinical utility using a randomized Design. clinicaltrials.gov, 2022 (Available at:) (Accessed May 5, 2022)
Article info
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
